Physician profile
Michael E Orzo
NPI 1548225287
$10,142.48
in general payments reported to CMS, 2019-2025
30 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $790 · 2021: $662 · 2022: $1,607 · 2023: $2,275 · 2024: $2,214 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,650.00 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Abbvie INC. | $1,506.14 | 2021-2025 | |
| Si-Bone, INC. | $670.76 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $584.13 | 2019-2024 | Xtampza, Belbuca |
| Pfizer INC. | $547.53 | 2019-2025 | |
| Medtronic, INC. | $468.03 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Scilex Pharmaceuticals INC. | $416.18 | 2019-2023 | Ztlido |
| Vertos Medical, INC. | $376.54 | 2020-2023 | Mild Device Kit |
| Ibsa Pharma INC. | $376.47 | 2020-2025 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.30 | 2022-2025 | Relistor |
| Biotronik Nro, INC. | $264.77 | 2025 | Prospera |
| Biodelivery Sciences International, INC. | $259.78 | 2019-2021 | |
| Nevro Corp. | $242.50 | 2019-2021 | |
| Abbott Laboratories | $237.64 | 2020-2024 | Eterna |
| Stryker Corporation | $199.77 | 2024 | Mild Device Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $149.13 | 2024-2025 | |
| Saluda Medical Americas, INC. | $123.46 | 2024 | Evoke |
| Allergan, INC. | $105.56 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $87.09 | 2022 | |
| Nalu Medical, INC. | $81.46 | 2020-2022 | |
| Curonix LLC | $80.75 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lundbeck LLC | $79.34 | 2022-2025 | Vyepti |
| Medtronic USA, INC. | $78.11 | 2019-2020 | |
| Almatica Pharma LLC | $70.73 | 2023 | Gralise |
| Spr Therapeutics, INC | $64.01 | 2023-2025 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $50.55 | 2020-2021 | |
| Tersera Therapeutics LLC | $20.43 | 2023 | Prialt |
| Pacira Pharmaceuticals Incorporated | $18.87 | 2023 | Zilretta, Iovera, Exparel |
| Fidia Pharma USA INC. | $15.36 | 2023 | Triluron, Hymovis |
| Relievant Medsystems, INC. | $9.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Orzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.